The prevalence of bone impairment at last follow-up was significantly higher in patients with persistent hyperprolactinemia than those with normoprolactinemia (42% vs. 15%; p = 0.04); in hypogonadal compared with eugonadal patients (33% vs. 10%; p = 0.01); and in patients with persistent sex hormone therapy compared to those without (46% vs. 10%; p < 0.001). The gene discussed is PLXNA3; the disease is hyperprolactinemia.